FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023807748> ?p ?o ?g. }

• W2023807748 endingPage "225" @default.
• W2023807748 startingPage "225" @default.
• W2023807748 abstract "Non-Hodgkin lymphoma symbolizes a heterogeneous group of diseases resulting from malignant transformation of lymphocytes with differing patterns of behavior and responses to treatment. The potential curability of non-Hodgkin lymphoma differs among the various histologic subtypes and is associated in part with the stage at presentation. CD19 antigen is a type I transmembrane glycoprotein belonging to the immunoglobulin Ig superfamily. CD19 is specifically expressed in normal and neoplastic B-cells. Recent study showed that in a mouse model, CD19 and c-Myc synergize functionally to accelerate B-cell lymphomagenesis, which is associated with increased disease severity. Specificity is the most important challenge in cancer therapeutics. Antibody-drug conjugates have the prospect of enhancing the therapeutic efficacy over unconjugated monoclonal antibodies through the selective delivery of cytotoxic agents to cancer cells. The ubiquitous expression of CD19 in these tumors, especially at an earlier stage and the property of efficient internalization, makes CD19 an attractive and affective target for antibody-drug conjugate therapy as compared to CD20. SAR3419 (huB4-DM4) is a novel antibody-drug conjugate that is composed of a humanized monoclonal IgG1 anti-CD19 antibody (huB4) attached to the potent cytotoxic drug, a maytansine derivative (DM4), through a cleavable disulfide cross-linking agent N-Succinimidyl-4-2-pyridyldithio butanoic acid (SPDB). The preclinical efficacy of maytansine derivative-anti-CD19 conjugate was demonstrated in our laboratory, and SAR3419 was found to be more effective than CHOP in a xenograft model. Phase I trials have also been conducted on the basis of preclinical studies that demonstrated promising antitumor activity with acceptable safety results in human B-cell lymphoma models. Additional trials are ongoing and will provide additional insight into the full potential of this novel drug." @default.
• W2023807748 created "2016-06-24" @default.
• W2023807748 creator A5019999054 @default.
• W2023807748 creator A5058386543 @default.
• W2023807748 creator A5065296584 @default.
• W2023807748 date "2013-08-01" @default.
• W2023807748 modified "2023-10-14" @default.
• W2023807748 title "Targeting CD19 in B-cell lymphoma: emerging role of SAR3419" @default.
• W2023807748 cites W1512026049 @default.
• W2023807748 cites W1548735291 @default.
• W2023807748 cites W1556788203 @default.
• W2023807748 cites W1605230984 @default.
• W2023807748 cites W1884715737 @default.
• W2023807748 cites W1971628209 @default.
• W2023807748 cites W1971738718 @default.
• W2023807748 cites W1988071588 @default.
• W2023807748 cites W1988217711 @default.
• W2023807748 cites W1994186346 @default.
• W2023807748 cites W1995467767 @default.
• W2023807748 cites W1998665610 @default.
• W2023807748 cites W2005411978 @default.
• W2023807748 cites W2010333278 @default.
• W2023807748 cites W2011118089 @default.
• W2023807748 cites W2014654561 @default.
• W2023807748 cites W2015635188 @default.
• W2023807748 cites W2023941836 @default.
• W2023807748 cites W2025754154 @default.
• W2023807748 cites W2032972450 @default.
• W2023807748 cites W2034609970 @default.
• W2023807748 cites W2039338567 @default.
• W2023807748 cites W2041142448 @default.
• W2023807748 cites W2048313558 @default.
• W2023807748 cites W2056405796 @default.
• W2023807748 cites W2058015212 @default.
• W2023807748 cites W2071717470 @default.
• W2023807748 cites W2073496055 @default.
• W2023807748 cites W2074519099 @default.
• W2023807748 cites W2086450075 @default.
• W2023807748 cites W2086800018 @default.
• W2023807748 cites W2094477446 @default.
• W2023807748 cites W2104187048 @default.
• W2023807748 cites W2108528694 @default.
• W2023807748 cites W2112083044 @default.
• W2023807748 cites W2117582823 @default.
• W2023807748 cites W2123439935 @default.
• W2023807748 cites W2127013298 @default.
• W2023807748 cites W2127249281 @default.
• W2023807748 cites W2130669641 @default.
• W2023807748 cites W2134168335 @default.
• W2023807748 cites W2136374191 @default.
• W2023807748 cites W2138404218 @default.
• W2023807748 cites W2139761471 @default.
• W2023807748 cites W2141681661 @default.
• W2023807748 cites W2142099365 @default.
• W2023807748 cites W2143749371 @default.
• W2023807748 cites W2143876351 @default.
• W2023807748 cites W2153665789 @default.
• W2023807748 cites W2154191201 @default.
• W2023807748 cites W2154643481 @default.
• W2023807748 cites W2154696313 @default.
• W2023807748 cites W2161113152 @default.
• W2023807748 cites W2161817637 @default.
• W2023807748 cites W2164337721 @default.
• W2023807748 cites W2164807675 @default.
• W2023807748 cites W2165800290 @default.
• W2023807748 cites W2169000897 @default.
• W2023807748 cites W2169578616 @default.
• W2023807748 cites W2309349001 @default.
• W2023807748 cites W2338405699 @default.
• W2023807748 cites W2413608171 @default.
• W2023807748 cites W2417522353 @default.
• W2023807748 cites W2574705612 @default.
• W2023807748 cites W2583926568 @default.
• W2023807748 cites W2586396530 @default.
• W2023807748 cites W2605539363 @default.
• W2023807748 cites W2912373397 @default.
• W2023807748 cites W60759546 @default.
• W2023807748 cites W85464595 @default.
• W2023807748 cites W158331316 @default.
• W2023807748 cites W2416295735 @default.
• W2023807748 doi "https://doi.org/10.2147/cmar.s45957" @default.
• W2023807748 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3767487" @default.
• W2023807748 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24023523" @default.
• W2023807748 hasPublicationYear "2013" @default.
• W2023807748 type Work @default.
• W2023807748 sameAs 2023807748 @default.
• W2023807748 citedByCount "16" @default.
• W2023807748 countsByYear W20238077482014 @default.
• W2023807748 countsByYear W20238077482015 @default.
• W2023807748 countsByYear W20238077482016 @default.
• W2023807748 countsByYear W20238077482017 @default.
• W2023807748 countsByYear W20238077482018 @default.
• W2023807748 countsByYear W20238077482020 @default.
• W2023807748 countsByYear W20238077482021 @default.
• W2023807748 countsByYear W20238077482022 @default.
• W2023807748 countsByYear W20238077482023 @default.
• W2023807748 crossrefType "journal-article" @default.
• W2023807748 hasAuthorship W2023807748A5019999054 @default.

• next